Format

Send to

Choose Destination
AAPS J. 2019 Jan 9;21(2):17. doi: 10.1208/s12248-018-0286-6.

What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing.

Author information

1
Certara, 100 Overlook Center, Suite 101, Princeton, New Jersey, 08540, USA. tom.polasek@certara.com.
2
Centre for Medicines Use and Safety, Monash University, Melbourne, Australia. tom.polasek@certara.com.
3
Certara, 100 Overlook Center, Suite 101, Princeton, New Jersey, 08540, USA.
4
Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK.
5
Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
6
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea.
7
Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea.
8
Janssen Research and Development, Lower Gwynedd Township, Pennsylvania, USA.
9
Korea Advanced Institute of Advanced Technology, Daedoek Innopolis, Daejeon, South Korea.
10
Department of Pharmacology and Clinical Pharmacology, Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea.
11
Faculty of Pharmacy, Haiphong University of Medicine and Pharmacy, Haiphong, Vietnam.

Abstract

Model-informed precision dosing (MIPD) is modeling and simulation in healthcare to predict the drug dose for a given patient based on their individual characteristics that is most likely to improve efficacy and/or lower toxicity in comparison to traditional dosing. This paper describes the background and status of MIPD and the activities at the 1st Asian Symposium of Precision Dosing. The theme of the meeting was the question, "What does it take to make MIPD common practice?" Formal presentations highlighted the distinction between genetic and non-genetic sources of variability in drug exposure and response, the use of modeling and simulation as decision support tools, and the facilitators to MIPD implementation. A panel discussion addressed the types of models used for MIPD, how the pharmaceutical industry views MIPD, ways to upscale MIPD beyond academic hospital centers, and the essential role of healthcare professional education as a way to progress. The meeting concluded with an ongoing commitment to use MIPD to improve patient care.

PMID:
30627939
DOI:
10.1208/s12248-018-0286-6

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center